{"id":4052,"date":"2025-07-08T18:39:35","date_gmt":"2025-07-08T15:39:35","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4052"},"modified":"2025-11-03T20:22:06","modified_gmt":"2025-11-03T17:22:06","slug":"taiho-pharmaceutical-tas-205-phase-3-clinical-trial-nct04587908","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/taiho-pharmaceutical-tas-205-phase-3-clinical-trial-nct04587908\/","title":{"rendered":"Taiho Pharmaceutical, TAS-205 Faz 3 Klinik \u00c7al\u0131\u015fmas\u0131n\u0131n Birincil Son Noktas\u0131n\u0131 Kar\u015f\u0131lamad\u0131\u011f\u0131n\u0131 Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Taiho Pharmaceutical, Duchenne kas distrofisi olan hastalarda TAS-205&#039;nin (Pizuglanstat) faz III, randomize, plasebo kontroll\u00fc, \u00e7ift k\u00f6r ve a\u00e7\u0131k etiketli uzatma \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131n\u0131n, \u00e7al\u0131\u015fman\u0131n ayaktan kohortunda birincil sonlan\u0131m noktas\u0131 olan yerden kalkma s\u00fcresinde ba\u015flang\u0131\u00e7 seviyesine g\u00f6re 52. haftaya kadar ortalama de\u011fi\u015fimde anlaml\u0131 bir fark g\u00f6stermedi\u011fini duyurdu.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#tas-205-phase-3-clinical-study\">TAS-205 Faz 3 Klinik \u00c7al\u0131\u015fmas\u0131 NCT04587908<\/a><\/li><li><a href=\"#what-is-tas-205\">TAS-205 nedir?<\/a><\/li><li><a href=\"#tas-205-dmd-therapy-misses-the-mark-in-phase-iii-trial\">TAS-205 DMD Terapisi 3. Faz Denemesinde Hedefi Ka\u00e7\u0131rd\u0131<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"tas-205-phase-3-clinical-study\">TAS-205 Faz 3 Klinik \u00c7al\u0131\u015fmas\u0131 NCT04587908<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00e7al\u0131\u015fman\u0131n ayaktan kohortu, 5 ya\u015f ve \u00fczeri erkek DMD hastalar\u0131nda plasebo kontroll\u00fc, \u00e7ok merkezli, \u00e7ift k\u00f6r kar\u015f\u0131la\u015ft\u0131rmal\u0131 bir \u00e7al\u0131\u015fma olarak Japonya&#039;da y\u00fcr\u00fct\u00fclm\u00fc\u015ft\u00fcr. Bu \u00e7al\u0131\u015fman\u0131n amac\u0131, 52 hafta boyunca g\u00fcnde iki kez oral yoldan TAS-205 veya plaseboyu uygulayarak TAS-205&#039;nin etkinli\u011fini de\u011ferlendirmektir. Kas\u0131m 2020&#039;den Aral\u0131k 2023&#039;e kadar 26 merkezde toplam 82 hasta kaydedildi. Bu \u00e7al\u0131\u015fmadan elde edilen ayr\u0131nt\u0131l\u0131 sonu\u00e7lar, uygun bir akademik konferansta sunulacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04587908\" target=\"_blank\" rel=\"noopener\">TAS-205 Faz 3 Klinik \u00c7al\u0131\u015fmas\u0131<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-tas-205\">TAS-205 nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">TAS-205 (INN: pizuglanstat), Taiho Pharmaceutical taraf\u0131ndan ke\u015ffedilen se\u00e7ici hematopoietik prostaglandin D sentaz (HPGDS*) inhibit\u00f6r\u00fcd\u00fcr. DMD hastalar\u0131nda motor fonksiyonlardaki d\u00fc\u015f\u00fc\u015f\u00fc, DMD hastalar\u0131n\u0131n kaslar\u0131ndaki inflamatuar yan\u0131t\u0131 \u015fiddetlendiren HPGDS&#039;yi inhibe ederek kontrol eden, distrofin gen mutasyon tipinden ba\u011f\u0131ms\u0131z olarak kullan\u0131labilen bir DMD tedavisi olarak geli\u015ftirilmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>*HPGDS<\/strong>: Hematopoietik prostaglandin D sentaz<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"tas-205-dmd-therapy-misses-the-mark-in-phase-iii-trial\">TAS-205 DMD Terapisi 3. Faz Denemesinde Hedefi Ka\u00e7\u0131rd\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Taiho, pizuglanstat veya REACH-DMD&#039;nin gelece\u011fine de\u011finmese de, \u00e7al\u0131\u015fman\u0131n bulgular\u0131n\u0131 gelecekteki bir t\u0131p konferans\u0131nda sunaca\u011f\u0131n\u0131 belirtti. \u0130la\u00e7 i\u00e7in klinik \u00e7al\u0131\u015fmalar Japonya d\u0131\u015f\u0131nda ba\u015flamam\u0131\u015f gibi g\u00f6r\u00fcn\u00fcyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD toplulu\u011fu, pizuglanstat&#039;\u0131n hastal\u0131\u011fa neden olan distrofin gen mutasyonunun t\u00fcr\u00fcnden ba\u011f\u0131ms\u0131z olarak uygulanabilen DMD i\u00e7in potansiyel bir tedavi olarak tan\u0131t\u0131lmas\u0131ndan bu yana sonu\u00e7tan hayal k\u0131r\u0131kl\u0131\u011f\u0131na u\u011frad\u0131. DMD i\u00e7in yeni bir tedavi stratejisi, DMD hastalar\u0131n\u0131n kaslar\u0131ndaki inflamatuar yan\u0131t\u0131 yo\u011funla\u015ft\u0131ran HPGDS&#039;ye odaklanmay\u0131 i\u00e7eriyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Capricor Therapeutics taraf\u0131ndan olu\u015fturulan DMD kardiyomiyopatisi i\u00e7in bir h\u00fccre terapisi (deramiocel), bu ay\u0131n sonlar\u0131nda bir FDA dan\u0131\u015fma komitesi taraf\u0131ndan incelenmek \u00fczere planlanm\u0131\u015ft\u0131r. Ek olarak, bir gen terapisi se\u00e7ene\u011fi olan Sarepta\/Roche&#039;nin Elevidys&#039;si (delandistrogene moxeparvovec) vard\u0131r, ancak bu, y\u00fcr\u00fcyemeyen DMD hastalar\u0131nda akut karaci\u011fer yetmezli\u011finin neden oldu\u011fu hasta \u00f6l\u00fcmlerinden etkilenmi\u015ftir.<\/p>","protected":false},"excerpt":{"rendered":"<p>Taiho Pharmaceutical announced that the results of a phase III, randomized, placebo-controlled, double-blind and open-label, extension study of TAS-205 (Pizuglanstat) in patients with Duchenne muscular dystrophy showed no significant difference in the mean change from baseline to 52 weeks in the time to rise from the floor, which was the primary endpoint in the ambulatory [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4055,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[384,383,382],"class_list":["post-4052","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-pizuglanstat","tag-taiho-pharmaceutical","tag-tas-205"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4052"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4052\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4055"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}